Biologic agents are emerging as an important treatment for juvenile idiopathic arthritis (JIA), but the long-term safety of these therapies is a major concern and currently not completely understood. This Review examines available data for the safety of biologic therapies for JIA and details the serious adverse events associated with each agent as well as outlining the safety issues that need further study.
- Philip J. Hashkes
- Yosef Uziel
- Ronald M. Laxer
